This text is a result of machine translation.
AstraZeneca in China: Opportunities and Challenges [1/2]
AstraZeneca is a British pharmaceutical company founded in 1999 that focuses on discovering, developing, and commercializing prescription medicines in oncology, rare diseases, and biological medicals for cardiovascular, renal, metabolism, respiratory and immunology diseases.
Jul 05, 2022 03:21 PM
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Bai chongen: it is suggested to use the price mechanism to distribute electricity and distribute the carbon emission quota to end users
AI-driven Pharmaceutical Company Phil Rivers Nets Hundreds of Mns of CNY in Series A Round
Phil Rivers, incubated by the Institute of Computing Technology of the Chinese Academy of Sciences, is a platform company that drives drug discovery with 'computational medicine'.
Yesterday 10:08 PM
Yi Ming ang Ke delivers a statement to the main board of the Hong Kong stock exchange to develop a new generation of tumor immunotherapy
Precision Autoimmune Therapeutics Earned CNY 140 Mn in Angel Financing Round
Biotech firm Precision Autoimmune Therapeutics, specializing in the research and development of innovative drugs for autoimmune diseases, will focus on the precise therapies of autoimmune diseases.
Jul 06, 2022 09:53 PM
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
30 Chinese Low-Carbon Tech Companies You May Want to Get to Know「2/2」
Jul 06, 2022 02:24 PM
30 Chinese Low-Carbon Tech Companies You May Want to Get to Know「1/2」
Jul 06, 2022 12:06 PM